OneTouch Vibe™ Plus System

Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor

FDA Premarket Approval P130007 S016

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the onetouch vibe plus system is indicated for continuous subcutaneous insulin infusion for the management of insulin-requiring diabetes. It can be used solely for continuous insulin delivery and as part of the onetouch vibe plus system to receive and display continuous glucose measurements from the dexcom g5® sensor and transmitter. The onetouch vibe plus system's continuous glucose monitoring (cgm) is indicated for detecting trends and tracking patterns in persons (ages 2 and older) with diabetes, and is intended to complement, not replace, information obtained from standard home glucose monitoring devices. Cgm aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments, which may minimize these excursions. Interpretation of results from the dexcom g5® sensor and transmitter should be based on the trends and patterns seen with several sequential readings over time. The system is intended for single patient use and requires a prescription. The animas® vibe® system’s continuous glucose monitoring (cgm) is indicated for detecting trends and tracking patterns in persons (age 2 and older) with diabetes, and is intended to complement, not replace, information obtained from standard home glucose monitoring devices. Cgm aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments, which may minimize these excursions. Interpretation of results from the dexcom g5® sensor and transmitter should be based on the trends and patterns seen with several sequential readings over time. The system is intended for single patient use and requires a prescription.

DeviceOneTouch Vibe™ Plus System
Classification NamePump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor
Generic NamePump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor
ApplicantANIMAS CORP.
Date Received2016-06-06
Decision Date2016-12-16
Notice Date2016-12-20
PMAP130007
SupplementS016
Product CodeOYC
Docket Number16M-4458
Advisory CommitteeClinical Chemistry
Supplement TypePanel Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address ANIMAS CORP. 965 Chesterbrook Blvd. wayne, PA 19087
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P130007Original Filing
S036 2018-06-18 30-day Notice
S035 2018-03-20 30-day Notice
S034 2018-02-20 30-day Notice
S033 2018-01-30 30-day Notice
S032
S031 2017-09-29 30-day Notice
S030
S029 2017-07-18 30-day Notice
S028
S027 2017-06-02 135 Review Track For 30-day Notice
S026 2017-05-11 30-day Notice
S025
S024 2017-03-24 30-day Notice
S023 2017-03-22 30-day Notice
S022 2016-09-19 Real-time Process
S021
S020 2016-08-18 30-day Notice
S019 2016-07-29 Real-time Process
S018 2016-07-26 30-day Notice
S017
S016 2016-06-06 Panel Track
S015 2016-05-02 30-day Notice
S014 2016-04-21 Real-time Process
S013 2016-04-12 30-day Notice
S012 2016-04-07 Real-time Process
S011 2016-03-17 Real-time Process
S010 2016-02-05 30-day Notice
S009 2015-09-21 30-day Notice
S008 2015-08-20 Real-time Process
S007 2015-07-21 30-day Notice
S006 2015-07-13 30-day Notice
S005 2015-07-06 Real-time Process
S004 2015-04-30 Panel Track
S003 2015-04-10 135 Review Track For 30-day Notice
S002 2015-03-26 Real-time Process
S001 2015-01-23 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.